⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441833 | 0.72 | — | — | |
| SCHEMBL16910012 | 0.69 | TDP1 (0.57) | — | |
| SCHEMBL5954330 | 0.67 | — | — | |
| SCHEMBL15740350 | 0.67 | — | — | |
| Isopropyl Alcohol SCHEMBL28940631 | 0.62 | — | — | |
| SCHEMBL3836561 | 0.62 | TDP1 (0.36) | — | |
| SCHEMBL5490951 | 0.61 | — | — | |
| Bromide SCHEMBL3425347 | 0.60 | TDP1 (0.33) | — | |
| SCHEMBL1078973 | 0.60 | TDP1 (0.67) | — | |
| SCHEMBL28394174 | 0.60 | TDP1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049309-A1 | REGULATION OF ACTIVITY OF RNAI MOLECULES | NOVO NORDISK AS (DE) | 2026-02-19 | — | — | US | disclosed |
| EP-4337773-A1 | LIPID CONJUGATION FOR TARGETING NEURONS OF THE CENTRAL NERVOUS SYSTEM | Dicerna Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024040041-A1 | REGULATION OF ACTIVITY OF RNAI MOLECULES | DICERNA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4284933-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM | Dicerna Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023081500-A2 | RNAi OLIGONUCLEOTIDE CONJUGATES | DICERNA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081823-A1 | LIPID CONJUGATION FOR TARGETING ASTROCYTES OF THE CENTRAL NERVOUS SYSTEM | DICERNA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081822-A1 | LIPID CONJUGATION FOR TARGETING OLIGODENDROCYTES OF THE CENTRAL NERVOUS SYSTEM | DICERNA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-1468007-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | Human Genetic Signatures PTY Ltd. (AU) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003052133-A2 | OLIGONUCLEOTIDE ANALOGUES COMPRISING INTERCALATOR PSEUDONUCLEOTIDES | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003052134-A2 | OLIGONUCLEOTIDES COMPRISING INTERCALATOR PSEUDONUCLEOTIDE(S) FOR DETECTION OF NUCLEIC ACIDS AND MUTANTS HEREOF | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003052132-A2 | LINEAR AND HAIRPIN OLIGONUCLEOTIDE ANALOGUES COMPRISING INTERCALATOR PSEUDONUCLEOTIDES | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051901-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |